Anuh Pharma Limited has informed the Exchange about Investor Presentation
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anuh Pharma reported Q1 FY26 operating revenue of ₹186.48 crores, up 35% year-on-year, driven by strong export growth and expanded customer reach. However, profitability took a hit with EBITDA at ₹13.68 crores (margin 7.34% vs 10.36% last year) and PAT declining 12.7% YoY to ₹8.30 crores, as the company faced input cost pressures. Management expressed confidence that process efficiencies, utility optimisation, and higher-margin product sales will help restore margins in upcoming quarters. The company is part of the SK Group, derives 55% of revenue from exports across 59 countries, and is one of India's largest manufacturers of Macrolides and Anti-TB APIs. Future strategy targets 15-16% annual growth, with focus on complex chemistry APIs for lifestyle diseases (diabetes, hypertension, obesity).
The strong 35% revenue growth is positive, but shrinking EBITDA margins and a 12.7% drop in PAT may concern investors focused on near-term profitability. Management's margin recovery guidance and pipeline of new products in diabetes and anti-TB segments could be potential upside catalysts if execution delivers.